MicroFab receives a Phase II SBIR award from the National Science Foundation for the development of an ink-jet based calibrators for explosives detectors. MicroFab receives a Phase II SBIR award from National Institute of Health for the development of an ink-jet based system for protein crystallization. MicroFab receives SBIR award from National Institute of Health for the development of an ink-jet based system for MALDI MS Imaging.. MicroFab receives SBIR award from National Institute of Health for the development of an ink-jet based system for Western blot studies. MicroFab receives SBIR award from National Institute of Health for the development of an ink-jet based system for membrane protein crystallization. MicroFab receives SBIR award from National Science Foundation for the development of a vapor generator for the calibration of explosive trace detectors NIST presentations on the use of AromaJet technology and JetLab printers in Homeland security. MicroFab receives SBIR award from National Institute of Health for the development of an ink-jet based coating system for drug coated cardiovascular stents. MicroFab's technology and equipment at the heart of 2004 R&D 100 Award winning product. MicroFab receives first UL recognition for products. Shimadzu BioTech's Chemical Inkjet Printer (ChIP), a Proteomics platform containing MicroFab hardware as the heart of the technology, is now shipping. ASME North Texas Section presents MicroFab Technologies, Inc. the "NTS Industry Award" MicroFab receives Phase II SBIR award from the National Institutes of Health to develop an “LC Microdispenser for High Resolution MALDI-TOF Analysis.” MicroFab Technologies receives Phase II SBIR award from the National Institute of Neurological Disorders and Stroke (NIH) titled “Ink-Jet Printed Nerve Conduits.” MicroFab ink-jet technology featured in Albion Biotech talk at October 2002 PIRA conference entitled "Tomorrow's Markets for InkJet Printing" in Leatherhead, UK. [ home | about us | equipment | services | technology | news | contact us ]